American Society of Hematology Selects 30 Medical Students and Residents for 2016 HONORS Award
(WASHINGTON – July 6, 2016) The American Society of Hematology (ASH) today announced the names of 15 medical students and 15 residents selected to receive the 2016 ASH HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award.
The ASH HONORS Award aims to support the career development of talented North American medical students and residents interested in hematology. Recipients receive a stipend of $5,000 to conduct either short-term (up to three months) or long-term hematology research projects (between three and 12 months) and $1,000 each year for two years to support their attendance at a program orientation at the ASH annual meeting. Each HONORS participant will have an ASH member research mentor who will assist and oversee the awardee’s work and progress.
“By supporting hematologists-in-training early in their research careers, it is our goal to encourage talented medical students and residents to continue to pursue careers in hematology,” said ASH President Charles S. Abrams, MD, of the University of Pennsylvania. “We look forward to watching their promising careers unfold.”
The 2016 ASH HONORS Award recipients are:
Medical Students:
| Recipients | Research Topics |
|
Arielle Abovich |
IPS derived CD38-targeted CAR T-cell generation in multiple myeloma |
|
Ana Luiza Altaffer |
Adoptive T-cell therapy for elimination of factor VIII inhibitors |
|
Rahul Bhansali |
Uncovering the mechanism of DYRK1A in lymphopoiesis and acute lymphoblastic leukemia |
|
Michelle Chen |
Determination of the role of splicing factor 3B Subunit 1 (SF3B1) mutations in MDS pathogenesis |
|
Sean Dougherty |
Accelerated immunoaging following immune reconstitution in long-term survivors of allogeneic hematopoietic stem cell transplantation |
|
Richard Godby |
Duffy antigen receptor for chemokines expressed on red blood cells: a new player in vascular dysfunction |
|
Naomi Gunawardena |
Is mitochondrial aconitase required for erythropoiesis? |
|
Parisa Khalighi |
The role of PAR4 polymorphisms in sickle cell disease |
|
Jerry Lee |
Universal off-the-shelf T-cell therapy for B-cell malignancies |
|
Orly Leiva |
The role of lysyl oxidase in facilitating JAK2V617F mutation-induced myelofibrosis |
|
Vivian Liu |
Understanding mechanisms of venetoclax resistance in B-cell malignancies |
|
Ariel Siegel |
Role of RAB5 in erythropoiesis |
|
Ishan Tatake |
Folate receptor expression on CAR T-cells as a mechanism for in vivo imaging and T-cell elimination |
|
Elsa Treffeisen |
The in vivo role of NETs in HIT |
|
Christopher Tricarico |
Determining the effect of ATRA on chromatin structure and transcription in acute promyelocytic leukemia |
Residents:
| Recipients | Research Topics |
|
Kathryn Bradford, MD |
Analysis of busulfan pharmacokinetics in patients treated with gene therapy |
|
Joseph Clara, MD |
Single institution experience in the management of CD30+ lymphoproliferative disorders |
|
Nicole Cruz, MD |
Optimized assessment of the leukemia stem cell marker CD123 to guide therapy |
|
Kyle Davis, MD |
Hematuria in hemophilia patients found on routine urinalysis |
|
Susan DeWolf, MD |
A new window into the human alloresponse via high-throughput T-cell receptor sequencing |
|
Harold Elias, MD |
Post-transcriptional regulation of gene expression in hematopoietic stem cells |
|
Karine Gauthier, MD |
Preventing maternal mortality: VTE prophylaxis with LMWH in the postpartum period, a before and after study |
|
Ashwin Kishtagari, MD |
Clinical outcomes of MDS patients who are medically eligible for allogeneic stem cell transplant |
|
Harry Lesmana, MD |
Elucidating the roles of Ras-RGL2-Ral pathway in erythropoiesis |
|
Konstantinos Lontos, MD |
Semaphorin 4D in multiple myeloma |
|
Luis Malpica Castillo, MD |
Targeting CD30 expression in adult T-cell leukemia-lymphoma (ATL) |
|
Rushad Patell, MD |
Identifying predictors for stroke in patients with cancer and atrial fibrillation; a cohort study. |
|
Praful Ravi, MD |
Evolving changes in disease biomarkers and risk of progression in smoldering multiple myeloma. |
|
Chris Reilly, MD |
Clinical outcomes of transjugular intrahepatic portosystemic shunt procedure for MPN-associated portal hypertension |
|
Sarah Rumler, MD |
Neurocognitive effect of red blood cell transfusion in pediatric oncology patients with anemia secondary to myelosuppressive chemotherapy |
The American Society of Hematology (www.hematology.org) is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.
CONTACT:
Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission